SVF Endurance (Cayman) Ltd sold $160k of VIR
owner at Vir Biotechnology, Inc.. 24,553 shares at an average of $6.50, traded Oct 28, 2025, filed Oct 30, 2025.
Score components
- +12Role10% owner
- +11Trade size$160k at market
- 0Share of holdings soldSold 0.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-25-020240, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2025 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -24,453 | $6.50 | $159k | 14,574,083 | Oct 30, 2025 |
| Oct 29, 2025 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -100 | $6.49 | $649 | 14,573,983 | Oct 30, 2025 |
Related signals
Other insiders at Vir Biotechnology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Vir Biotechnology, Inc. | Brent Sabatini SVP, Chief Accounting Officer | $70k 7,711 shares | -11% | |
| 22Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $209k 22,000 shares | -2% | |
| 31Weak | Vir Biotechnology, Inc. | Marianne De Backer Chief Executive Officer | $141k 14,762 shares | -1% | |
| 16Weak | Vir Biotechnology, Inc. | Mark Eisner EVP and Chief Medical Officer | $34k 3,505 shares | -2% | |
| 17Weak | Vir Biotechnology, Inc. | Jason O'Byrne EVP & Chief Financial Officer | $16k 1,634 shares | -1% | |
| 11Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $413k 42,377 shares | -4% | |
| 10Weak | Vir Biotechnology, Inc. | Brent Sabatini SVP, Chief Accounting Officer | $14k 1,430 shares | -2% | |
| 26Weak | Vir Biotechnology, Inc. | Vanina de Verneuil EVP, General Counsel, Corp Sec | $164k 16,817 shares | -13% | |
| 31Weak | Vir Biotechnology, Inc. | Marianne De Backer Chief Executive Officer | $142k 19,039 shares | -2% | |
| 10Weak | Vir Biotechnology, Inc. | Mark Eisner EVP and Chief Medical Officer | $16k 2,089 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.